Anti-HER2 ribozyme (Elan/Sirna)

N/A

Report date: 2025/12/16 17:45:59

Base Information

Drug NameAnti-HER2 ribozyme (Elan/Sirna)
Drug Alias NameHerzyme
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Ribozyme
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsRNA inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2Ribonucleic Acid
Therapy Area/IndicationsOvarian NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerckElan Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesElan Pharmaceuticals IncMerck & Co Inc
Active IndicationsN/A
Inactive IndicationsOvarian NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A